Aleksandar Cetkovic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Aleksandar Cetkovic has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Aleksandar Ljubić
1 shared publicationAndreja Glišić
1 shared publicationDragana Miljic
1 shared publicationJelena Stamenković
1 shared publication- Marina Djurovic
Klinicki centar Srbije, Institut za endokrinologiju, dijabetes i bolesti metabolizma, Beograd, Srbija
1 shared publication Marina Nikolic-Djurovic
1 shared publication
Latest Publications
- 18 October 2011
- Published by Taylor & Francis in Endocrine Research
- Vol. 37 (2) , 78-88
Plasma Kisspeptin Levels in Pregnancies with Diabetes and Hypertensive Disease as a Potential Marker of Placental Dysfunction and Adverse Perinatal Outcome
The aim of this study was to prospectively evaluate plasma kisspeptin levels in 129 singleton pregnancies with diabetes [pregestational insulin-dependent diabetes mellitus (type 1) and gestational diabetes (GD)] and hypertensive disease [chronic hypertension (CH), gestational hypertension, and preeclampsia (PE)] as a potential marker of placental dysfunction and adverse perinatal outcome. Kisspeptin levels were evaluated in the first, second, and third trimesters in patients with type 1 diabetes (16 patients), H (22), and healthy control (25) and in the second and third trimesters in patients with GD (20), gestational hypertension (18), and PE (28). Maternal kisspeptin levels were correlated with pregnancy outcome, parameters of fetoplacental circulation, ultrasound-detected abnormalities of placental morphology, and placental weight at delivery. In pregnancies with type 1 diabetes and H, mean kisspeptin levels were significantly lower compared with the control group (p<0.001 in the first and second trimesters and p<0.05 in the third trimester). Decreased plasma kisspeptin levels in the second and third trimesters were found in patients with GD (p<0.001 in the second and third trimesters) and PE (p<0.001 in the second trimester and p<0.05 in the third trimester). In patients with PE and placental dysfunction, low kisspeptin levels in the third trimester were associated with adverse perinatal outcome. Our study demonstrates reduced kisspeptin levels in pregnancies with diabetes, H, PE, and placental dysfunction. In patients with PE and placental dysfunction, decreased kisspeptin levels were associated with adverse perinatal outcome. Larger studies are needed to investigate the role of kisspeptin as a potential marker of placental dysfunction and adverse perinatal outcome.
- 18 October 2011
- Published by Taylor & Francis in Endocrine Research
- Vol. 37 (2) , 78-88
Plasma Kisspeptin Levels in Pregnancies with Diabetes and Hypertensive Disease as a Potential Marker of Placental Dysfunction and Adverse Perinatal Outcome
The aim of this study was to prospectively evaluate plasma kisspeptin levels in 129 singleton pregnancies with diabetes [pregestational insulin-dependent diabetes mellitus (type 1) and gestational diabetes (GD)] and hypertensive disease [chronic hypertension (CH), gestational hypertension, and preeclampsia (PE)] as a potential marker of placental dysfunction and adverse perinatal outcome. Kisspeptin levels were evaluated in the first, second, and third trimesters in patients with type 1 diabetes (16 patients), H (22), and healthy control (25) and in the second and third trimesters in patients with GD (20), gestational hypertension (18), and PE (28). Maternal kisspeptin levels were correlated with pregnancy outcome, parameters of fetoplacental circulation, ultrasound-detected abnormalities of placental morphology, and placental weight at delivery. In pregnancies with type 1 diabetes and H, mean kisspeptin levels were significantly lower compared with the control group (p<0.001 in the first and second trimesters and p<0.05 in the third trimester). Decreased plasma kisspeptin levels in the second and third trimesters were found in patients with GD (p<0.001 in the second and third trimesters) and PE (p<0.001 in the second trimester and p<0.05 in the third trimester). In patients with PE and placental dysfunction, low kisspeptin levels in the third trimester were associated with adverse perinatal outcome. Our study demonstrates reduced kisspeptin levels in pregnancies with diabetes, H, PE, and placental dysfunction. In patients with PE and placental dysfunction, decreased kisspeptin levels were associated with adverse perinatal outcome. Larger studies are needed to investigate the role of kisspeptin as a potential marker of placental dysfunction and adverse perinatal outcome.
- Open Access
- 1 January 2007
- Published by National Library of Serbia in Vojnosanitetski Pregled
- Vol. 64 (4) , 231-234
Neonatal outcome in pregnancies complicated with pregestational diabetes mellitus
Background/Aim. Pregestational diabetes mellitus (PGDM) represents glucose intolerance that begins before pregnancy and is followed by the increased risk of neonatal and maternal complications. The aim of this study was to establish neonatal outcome in pregnancies with pregestational diabetes mellitus and the factors that had influence on it. Methods. This study included 27 pregnant women with insulin-dependant PGDM hospitalized during 2004 in the Institute for Obstretics and Gynecology, Clinical Center of Serbia, Belgrade. The control group consisted of 2 292 healthy pregnant women presented to the Institute within 2004. Results. Twenty-three (85%) infants of the women with PGDM had complications in comparison with 356 (15.5%) infants of the women in the control group, that was statistically significant difference (p < 0.001). Macrosomia was present in 8 (29.6%) and birth injuries in 6 (22.2%) infants of women with PGDM that was statistically significant difference (p < 0.001) in comparisom with the women in the control group who had 194 (8.5%) infants with macrosomia and 156 (6.8%) infants with birth injuries. The women with PGDM had 3 (11.1%) neonatal deaths and 3 (11.1%) infants were born with congenital malformations in comparison with the women in the control group without these complications. We established statisticaly significant correlation (p < 0.001) between glicoregulation before and during pregnancy in the women with PGDM and neonatal outcome. Conclusion. The incidence of neonatal morbidity and mortality in the women with PGDM was significantely more frequent as compared with the normal population. Achieving optimal maternal glucose levels in women with PGDM both preconceptionally and during pregnancy is associated with significant reduction of neonatal complications.
- 1 January 2007
- Published by National Library of Serbia in Vojnosanitetski Pregled
- Vol. 64 (4) , 231-234
Open AccessNeonatal outcome in pregnancies complicated with pregestational diabetes mellitus
Background/Aim. Pregestational diabetes mellitus (PGDM) represents glucose intolerance that begins before pregnancy and is followed by the increased risk of neonatal and maternal complications. The aim of this study was to establish neonatal outcome in pregnancies with pregestational diabetes mellitus and the factors that had influence on it. Methods. This study included 27 pregnant women with insulin-dependant PGDM hospitalized during 2004 in the Institute for Obstretics and Gynecology, Clinical Center of Serbia, Belgrade. The control group consisted of 2 292 healthy pregnant women presented to the Institute within 2004. Results. Twenty-three (85%) infants of the women with PGDM had complications in comparison with 356 (15.5%) infants of the women in the control group, that was statistically significant difference (p < 0.001). Macrosomia was present in 8 (29.6%) and birth injuries in 6 (22.2%) infants of women with PGDM that was statistically significant difference (p < 0.001) in comparisom with the women in the control group who had 194 (8.5%) infants with macrosomia and 156 (6.8%) infants with birth injuries. The women with PGDM had 3 (11.1%) neonatal deaths and 3 (11.1%) infants were born with congenital malformations in comparison with the women in the control group without these complications. We established statisticaly significant correlation (p < 0.001) between glicoregulation before and during pregnancy in the women with PGDM and neonatal outcome. Conclusion. The incidence of neonatal morbidity and mortality in the women with PGDM was significantely more frequent as compared with the normal population. Achieving optimal maternal glucose levels in women with PGDM both preconceptionally and during pregnancy is associated with significant reduction of neonatal complications.